Table 1.
Baseline characteristics, demographics, and treatment of all patients in the POOLED cohort
| Established CVD | CKD only* or CV risk factors only | POOLED cohort† | |
|---|---|---|---|
| N (%) | 4,720 (72.8) | CKD only 1,050 (16.2), CV risk factors only 710 (11.0) | 6,480 (100) |
| Age, years | 64.8 (7.6) | 66.9 (6.2) | 65.4 (7.3) |
| Sex, female, n (%) | 1,431 (30.3) | 871 (49.5) | 2,302 (35.5) |
| Diabetes duration, years | 14.2 (8.4) | 14.8 (8.1) | 14.4 (8.3) |
| Current smoker, n (%) | 604 (12.8) | 151 (8.6) | 755 (11.7) |
| BMI, kg/m2 | 32.4 (6.2) | 32.9 (6.7) | 32.5 (6.4) |
| HbA1c, mmol/mol | 68 (18) | 69 (16) | 68 (18) |
| HbA1c, % | 8.4 (1.6) | 8.5 (1.5) | 8.4 (1.6) |
| SBP, mmHg | 135 (17) | 137 (18) | 136 (17) |
| DBP, mmHg | 76 (10) | 77 (10) | 77 (10) |
| Total cholesterol, mmol/L, geometric mean (CoV) | 4.06 (28.10) | 4.35 (25.04) | 4.13 (27.41) |
| LDL cholesterol, mmol/L | 2.20 (0.92) | 2.40 (0.91) | 2.25 (0.92) |
| Non-HDL cholesterol, mmol/L | 3.10 (1.13) | 3.30 (1.09) | 3.15 (1.12) |
| Triglycerides, mmol/L | 2.07 (1.60) | 2.07 (1.56) | 2.06 (1.57) |
| eGFR, mL/min/1.73 m2‡ | 77 (21) | 70 (23) | 75 (22) |
Data are means (SD) unless otherwise indicated. CoV, coefficient of variation; CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.
*
eGFR <60 mL/min/1.73 m2 (estimated using the CKD-EPI creatinine equation) and no established CVD.
†
In total, 5,041 patients were treated with antithrombotic medication at baseline and 638 patients initiated treatment with antithrombotic medication during SUSTAIN 6 and PIONEER 6.
‡
Estimated using the CKD-EPI creatinine equation.